Generate Biomedicines, Inc.

$12.12 ▲ 3.31%

2026-04-21 07:03:00

Explore Generate Biomedicines, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap

$1.59 B

Current Price

$12.12

52W High / Low

$15.32 / $11

Stock P/E

—

Book Value

$-12.24

Dividend Yield

—

ROCE

-94.79%

ROE

-81.72%

Face Value

—

EPS

$-2.18

Exp Qtr EPS

—

Sector

Healthcare

Industry

Biotechnology

Employees

312

Beta

—

Debt / Equity

-0.11

Current Ratio

2.85

Quick Ratio

2.85

Forward P/E

-5.38

Price / Sales

45.6

Enterprise Value

—

EV / EBITDA

—

EV / Revenue

—

Rating

Strong Buy

Target Price

$25

EPS Forecast (FY)

—

ABOUT

In essence, generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. In essence, it uses protein-based modalities for drug development. In essence, its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In essence, in additional, it is focused on developing Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. In essence, was formerly known as Generate Biologics, Inc. In essence, and changed its name to Generate Biomedicines, Inc. In February 2020. In essence, this organization was incorporated in 2018 and is based in Somerville, Massachusetts. ROE at 38.68% based on the latest available annual data. ROCE at -94.79% using operating income and capital employed. Debt to equity stands at -0.11x. Operating margin is -737.04% on trailing numbers. Trailing twelve month sales are available in the dataset.

Pros

Healthy return on equity.
Balance sheet leverage appears manageable.
Short-term liquidity looks comfortable.
Valuation is not stretched on P/E basis.

Cons

Capital efficiency is modest.
Operating margin is thin.
Net margin is relatively low.

Sift Stocks

S.No.	Name	Price	P.E.	Market Cap	Div Yld %	ROCE	ROE	52Week High/ Low	Book Value
1.	Immunome, Inc.	$24.25	—	$2.79 B	—	-35.12%	-52.09%	$27.65 / $6.96	$5.61
2.	AEON Biopharma, Inc.	$1.07	—	$25.81 M	—	252.78%	-46.26%	$1.45 / $0.38	$-4.54
3.	KalVista Pharmaceuticals, Inc.	$20.87	—	$1.07 B	—	-89%	-121.5%	$21.3 / $9.83	$-0.05
4.	Adicet Bio, Inc.	$8.67	—	$83.2 M	—	-71.49%	-67.55%	$17.44 / $6.01	$14.82
5.	Evogene Ltd.	$0.8	—	$7.92 M	—	-84.53%	-1.01%	$2.42 / $0.72	$-0.01
6.	Galmed Pharmaceuticals Ltd.	$0.75	—	$4.81 M	—	-38.45%	-64.21%	$2.68 / $0.41	$3.49
7.	Tango Therapeutics, Inc.	$26.39	—	$3.8 B	—	-29.52%	-37.23%	$26.81 / $1.03	$2.55

Quarterly Results

Figures shown in M / B


Sales
Operating Profit
Net Profit
EPS in Rs

Profit & Loss

Figures shown in M / B

	2025	2024
Sales	31.89 M	20.46 M
Operating Profit	-235.06 M	-196.94 M
Net Profit	-203.15 M	-173.77 M
EPS in Rs	-1.59	-1.36

Balance Sheet

Figures shown in M / B

	2025	2024
Total Assets	330.18 M	518.26 M
Total Liabilities	953.38 M	953.35 M
Equity	-615.97 M	-434.52 M
Current Assets	234.37 M	407.49 M
Current Liabilities	82.2 M	86.63 M

Cash Flow

Last available yearly cash flow history

	2025	2024
Operating CF	-200.62 M	-117.75 M
Investing CF	116.77 M	-57.73 M
Financing CF	28.06 M	91.33 M
Free CF	-204.13 M	-121.2 M
Capex	-3.51 M	-3.45 M

5Y Margin & Growth History

Last 5 year derived history from yfinance annual statements

	2025	2024
Revenue Growth %	55.89%	—
Earnings Growth %	-16.91%	—
Profit Margin %	-636.99%	-849.36%
Operating Margin %	-737.04%	-962.6%
Gross Margin %	—	—
EBITDA Margin %	-653.71%	-800.16%

Dividend & Split History

Latest dividend and stock split events stored from yfinance

Dividend History

No dividend history available.

Stock Splits

No stock split history available.

Shareholding Pattern

Shares and value shown in M / B

Holder Name	Type	Shares	Value	% Out	Report Date
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund	Institutional	1.04 M	$14.24 M	0.01%	2026-02-28
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund	Institutional	0.31 M	$4.31 M	0%	2026-02-28
Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund	Institutional	0.26 M	$3.6 M	0%	2026-02-28
Fidelity Commonwealth Trust-Fidelity Nasdaq Composite Index ETF	Institutional	0.03 M	$0.39 M	0%	2026-02-28